From Penicillin to Digital Therapeutics and the Pace of Change in Life Sciences: Where are the Dollars Flowing?

Gain an overview of where the industry is going and where the industry can anticipate significant growth in the near future.

Register Free:
https://www.chromatographyonline.com/lcgc_w/penicillin

Event Overview:

The design of new therapies is changing at unprecedented pace. From small molecules regulating gene expression to protein degraders moving into digital therapies, and all of them with the safety levels required by the authorities.

This webinar will provide an overview of where the industry is going relative to life sciences investing and where the industry can anticipate significant growth in the near future (3‒5 years).

Key Learning Objectives:

• Understand the trends in life science investments
• Know which categories are anticipated to be high growth in the near term (2-5 years)
• Know which to anticipate regarding FDA approval in key disease states

Who Should Attend:

• Life science investors
• Organizations looking for M&A targets
• Payers looking to understand growth of biotech spending
• Companies looking to commercialize products in the next 12-36 months

Speaker:

Dean Erhardt, BBA, MBA
President & CE
OD2 Solutions

Mr. Dean Erhardt offers over 30 years of strategic marketing and management experience across both the consumer product and pharmaceutical arenas. Mr. Erhardt’s experience has spanned several Fortune 500 organizations, including Express Scripts, Cardinal Health, and U.S. Healthcare. Currently, Mr. Erhardt serves as President & CEO of D2 Solutions. In this capacity he leads the organization in working with a variety of industry stakeholders, including pharmaceutical, biotech, medical device, and e-Health companies working with channel partners including pharmacies, specialty pharmacies, specialty distribution, retail, long-term care, hospital/IDNs, payers, and PBMs. As CEO of D2 Solutions, Mr. Erhardt has also worked on various international projects in Albania, Algeria, South Korea, and Singapore. Mr. Erhardt is leading D2 Solutions through a transformation from a traditional consulting organization to a technology-driven organization, delivering SaaS solutions to industry stakeholders focused on driving revenue, enhancing operating margins, and lowering exposure to regulatory risk.

Prior to his role at D2, Mr. Erhardt served as Vice President of Sales and Marketing for the Express Scripts Specialty Pharmacy Benefits Management group. In this role, Mr. Erhardt worked with multiple managed care and payer organizations developing formularies, reimbursement models, and product support programs for specialty and biotech therapeutic categories. Prior to that position, Mr. Erhardt led Sales and Marketing for Express Scripts Specialty Distribution Services, working with over 30 pharmaceutical manufacturers in the areas of limited distribution programs, patient assistance programs, sampling, reimbursement support, and other product specific support programs. Mr. Erhardt has a Bachelor of Business Administration in Marketing from the University of Oklahoma and an MBA from the Keller Graduate School of Management. Mr. Erhardt has also participated in numerous executive management training programs and his board affiliations have included VirMedica, Inc. and StagesSTL.

Register Free:
https://www.chromatographyonline.com/lcgc_w/penicillin